DocMorris AG/€DOCM
1D1W1MYTD1Y5YMAX
Capital at risk
About DocMorris AG
DocMorris AG operates in the healthcare industry, focusing on providing pharmaceutical services as a leading online pharmacy in Europe. The company offers a wide range of prescription and over-the-counter medications, healthcare products, and services through its e-commerce platform. Founded in 2000, DocMorris is headquartered in Heerlen, the Netherlands. It holds a unique strategic position by leveraging digital technology to enhance customer convenience and streamline the medication procurement process. The company’s core strength lies in its extensive network and efficient delivery system, catering to a broad customer base across multiple European countries.
- Ticker
- €DOCM
- Sector
- Consumer Essentials
- Primary listing
- XGAT
- Employees
- 1,337
- Headquarters
- Frauenfeld, Switzerland
- Website
- corporate.docmorris.com/en
DocMorris AG Metrics
BasicAdvanced
€548M
-
-€2.76
1.86
-
Price and volume
Market cap
€548M
Beta
1.86
52-week high
€12.00
52-week low
€4.32
Average daily volume
443K
Financial strength
Current ratio
1.875
Quick ratio
1.529
Long term debt to equity
0.73
Total debt to equity
0.742
Interest coverage (TTM)
-4.92%
Profitability
EBITDA (TTM)
-79.879
Gross margin (TTM)
22.10%
Net profit margin (TTM)
-10.65%
Operating margin (TTM)
-7.25%
Effective tax rate (TTM)
-11.93%
Revenue per employee (TTM)
€929,620
Management effectiveness
Return on assets (TTM)
-6.37%
Return on equity (TTM)
-30.05%
Valuation
Price to revenue (TTM)
0.423
Price to book
1.39
Price to tangible book (TTM)
-4.31
Price to free cash flow (TTM)
-6.182
Free cash flow yield (TTM)
-16.17%
Free cash flow per share (TTM)
-1.771
Growth
Revenue change (TTM)
11.29%
Earnings per share change (TTM)
-55.78%
3-year revenue growth (CAGR)
9.55%
10-year revenue growth (CAGR)
3.22%
3-year earnings per share growth (CAGR)
-19.24%
10-year earnings per share growth (CAGR)
5.97%
Bulls say / Bears say
DocMorris delivered strong Q2 2026 revenue growth of 15.2% driven by a 45.8% surge in prescription (Rx) sales and an 80% jump in Digital Services, demonstrating robust demand across its platform. (Reuters)
The strategic partnership announced March 19, 2026 with Google will accelerate DocMorris’s AI-First transformation, leveraging Google’s Gemini models and cloud infrastructure to enhance its digital health platform and customer personalization. (Reuters)
A cost-saving initiative unveiled in June 2026 will cut 100 full-time roles and target CHF 15 million in annual savings through process automation, bolstering margin expansion and funding future growth. (Reuters)
CEPD's attempt to replace DocMorris AG’s supervisory board in March and the ensuing proxy battle risk diverting management attention and creating governance uncertainty. (Reuters)
Rival Redcare Pharmacy (formerly Shop Apotheke) reported an 18.4% rise in Q1 2026 revenue and a 58% jump in adjusted EBITDA, underscoring intensifying competition and narrowing DocMorris’s market share gains. (Reuters)
Despite top-line growth, DocMorris remained unprofitable with an adjusted EBITDA loss of CHF 6.3 million in Q1 2026, highlighting ongoing profitability and cash‐flow risks. (dpa-AFX)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.